EUVIMEDExplore EUVIMED
CrossrefInfo card

Analisi di costo-efficacia di rituximab più CHOP versus ProMACE-CytaBOM nel trattamento del linfoma diffuso a grandi cellule B: l’esperienza di Reggio Emilia

F. Merli, Roberto Ravasio, I. Alvarez De Cielis, F. Polcaro

Giornale Italiano di Health Technology Assessment · 2009

DOI: 10.1007/bf03320719 ↗
AbstractBibliographic details

Abstract

No abstract available.

Knowledge that fits your work.

From a free start through personal literature research to the complete Research Suite.

View plans →

Are all publisher full texts included?

No. Bibliographic records, abstracts and full texts are different content types. Full-text availability depends on the source, open access and your existing licences. An EUVIMED plan does not replace additional publisher rights.

View plans →